期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

急性冠脉综合征早期他汀类药物治疗的临床试验 被引量：8

暂未订购
导出
摘要 他汀类药物的调脂效应以及多方面的血管壁直接保护作用使之有可能在相对较短的时间内减慢或阻断急性不稳定冠状动脉病变的病理生理过程,因此,急性冠脉综合征早期开始他汀类药物治疗有可能减少心血管病事件,降低早期死亡率[1].
作者 施仲伟
机构地区 上海第二医科大学瑞金医院心脏科
出处 《中国医药导刊》 2002年第5期383-385,共3页 Chinese Journal of Medicinal Guide
关键词 急性冠脉综合征 他汀类药物 临床试验 疗效 ACS
分类号 R543.5 [医药卫生—心血管疾病]
  • 相关文献

参考文献17

  • 1施仲伟.急性冠脉综合征早期他汀类药物治疗的目的和机制[J].中国医药导刊,2002,4(2):125-126. 被引量：6
  • 2Kayikcioglu M, Turkoglu C, Kultursay H, et al. The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction. Circulation, 1999;100(18, Suppl I):I- 303
  • 3Arntz H - R, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (±colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] study). AmJ Cardiol, 2000; 86(12):1293 ～ 1298
  • 4Aronow HD, Topol EJ, Roe M, et al. Effect of lipid - lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet, 2001;357(9262): 1063 ～ 1068
  • 5Cannon CP, McCabe CH, Bentley J, et al. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS - TIMI 16. J Am Coil Cardiol, 2001; 37(2, Suppl A): 334A
  • 6Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS - HLA) . Early stat. in treatment following acute myocardial infarction and 1 - year survival. JAMA, 2001; 285(4) :430 ～ 436
  • 7McG uireDK, O'sheaJC, DykeCK, etal. Highlights fron the XXⅡI Congress of the European Society of Cardiology: August 26 to 30, 2000. Am Heart J, 2001;141(1): 164～ 172
  • 8Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA, 2001;285(13):1711～1718
  • 9ThackraySDR, WitteKKA, KhandA, etal. Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT,COPERNICUS, MERIT, CIBIS- Ⅱ, BEST, AMIOVIRT, V- MAC, BREAKTHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. Eur J Heart Fail, 2001 ;3(1): 117 ～ 124
  • 10SacksFM. Lipid - lowering therapy in acute coronary syndromes. JAMA, 2001;285(13): 1758- 1760

二级参考文献14

  • 1[1]Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444. patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344(8934):1383～1389
  • 2[2]Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med, 1996; 335(14): 1001～1009
  • 3[3]The Long - term Intervention with Pravastatin in Ischemic Disese (LIPID) Study Group. Prevention of cardiovsscular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med, 1998; 339(19): 1349～1357
  • 4[4]Sacks FM. Lipid - lowering therapy in acute coronary syndromes. JAMA,2001; 285(13) :1758～1760
  • 5[5]Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Prograrm. at the University of California Los Angeles. Am J Cardiol, 2000; 85(3A): 10A～17A
  • 6[6]Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implenentation of a cardiac hospitalization atherosclerosis management progeam (CHAMP). Am J Cardiol, 2001; 87(7):819～822
  • 7[7]Waters DD, Hsue PY. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes? Am J Cardiol, 2001; 88(suppl):7J～16J
  • 8[8]Waters D. Cholesterol lowering: should it continue to be the last thing we do? Circulation, 1999; 99(25) :3215～3217
  • 9[9]Gould KL, Martucci JP, Goldberg DI, et al. Short - term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium.Circulation, 1994; 89(4): 1530～1538
  • 10[10]O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-c o enzyme A reductase inhibitor, improves endothelial function within 1 nonth. Circulation, 1997; 95(5):1126～1131

共引文献5255

同被引文献27

  • 1尤巧英,李成江,李红,朱麒钱,斯徐伟.炎症因子与胰岛素抵抗和2型糖尿病大血管病变的相关性研究[J].中华流行病学杂志,2005,26(10):804-807. 被引量：27
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量：33100
  • 3高月,吴佳丽.初发2型糖尿病患者大血管病变与C反应蛋白的关系[J].浙江临床医学,2006,8(9):910-911. 被引量：4
  • 4殷忠,刘丽文,李兰荪,钱蕴秋,谢学建,王海昌.长期应用阿托伐他汀对冠心病患者颈动脉粥样斑块的影响[J].心脏杂志,2007,19(3):311-314. 被引量：11
  • 5Rosensen RS, Tang ney CC. Anti-atherombotie properties of statins: implications for cardiovascular event reduction[J]. JAMA, 1998,279(20) : 1643 - 1650.
  • 6Turner RC, Milins H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus, united kingdom prospective diabetes study[J]. BMJ, 1998,316(6) : 823 - 828.
  • 7Ridker PM, Cannon CP, Morrow D, et al. Creacfion protein level and outcomes after stafin therapy[ J ]. N Eng J Med, 2005,352 ( 1 ) : 20 - 28.
  • 8Harsch M, Bracsen JH, Niendarf A. Effects of low dose pravastatin sodium on plasma cholesterol levels and antiatherosclerosis of heterozygons WHHL rabbits fed a low choleseterol (0.03%) enriched diet for one year[ J ]. Atherosclerosis, 1997, 128(2) : 139 - 147.
  • 9Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecularweight heparin versus regular heparin on aspirin in thetreatment of unstable angina and silent ischemia. J AmColl Cardiol, 2005,26: 313.
  • 10Herrmann HC, Molitemo DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with orwithout abciximb in acute myocardial infarction: results from theSPEED ( GUSTO-4 pilot) Trial. JACC ,2000,36 : 1489-1496.

引证文献8

二级引证文献14

中国医药导刊
2002年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部